TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01416740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect MRA of shoulder
Description: Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate Dimeglumine
Description: Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
Study: NCT04619290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Methylene blue
Description: Patients will be received the treatment as follow: it will be placed Low Level Light Therapy (LLLT) NocUlite on the ventral side of the wrist on full power. Draw out 1ml of diluted Prexablu into a syringe. Activate this syringe LLLT device for 10 minutes. Then place 1ml of this activated solution of Prexablu sublingually. Patients must keep the solution under the tongue for 10 minutes before swallowing. Keep wrist pads on patients for 50 minutes.
Study: NCT00923000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: Nalbuphine 10mg with oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine 10mg with oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine with Long dan xie gan tang
Description: Morphine 10mg with oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine with Long dan xie gan tang
Description: Nalbuphine 10mg with Long dan xie gan tang 3g tid with oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nubian with Long dan xie gan tang
Description: Nalbuphine 10mg with Long dan xie gan tang 3g with oral administration
Study: NCT01781000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Fitness & Brain Training- Posit Science
Description: Computer aided cognitive program designed for intensive training of auditory perception, memory and attention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial Affect Training- FAT
Description: Computer-aided cognitive program designed for intensive training of facial affect discrimination, memory and attention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: standard treatment protocol of schizophrenia ward
Study: NCT01432379

Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: 155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
Study: NCT02075827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competitive video game
Description: 1 hour playing video game

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Little Big Planet
Description: 1 hour playing video game
Study: NCT00612430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Etoposide
Description: 32 pts w recurrent WHO grade III MG \& 27 pts w recurrent WHO grade IV MG will be enrolled in this study. Estimated rate of accrual is 10 pts per month. The estimated date of study completion is 6-9 months from study initiation. Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If pt tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day. The Duke investigators will review all la data \& order treatment. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent.
Study: NCT04099173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness Based Intervention
Description: This intervention will consist of four, 45 minute individual mindfulness training sessions (one session per day, over a range of 12 subsequent days) provided by a trained mindfulness facilitator.
Study: NCT04677881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: intervention group: bread with sourdough control group: bread with yeast

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intervention group
Description: intervention group: bread with sourdough control group: bread with yeast
Study: NCT00543608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iclaprim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iclaprim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Study: NCT00858962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg of raltegravir orally twice daily together with normally prescribed stable dose of buprenorphine for a minimum of 4 days and up to 14 days.
Study: NCT03933436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodine swabs.
Description: Children will then have their periurethral region gently cleansed for ten seconds with iodine swabs.
Study: NCT01323985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698
Description: 5mg-400mg IV (in the vein) single dose over 1-4 hours
Study: NCT03933436

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline flush.
Description: Children will then have their periurethral region gently cleansed for ten seconds with saline flush.
Study: NCT05000086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99Tc methylene diphosphonate
Description: 22mg qd，Once a day for 7 consecutive days
Study: NCT02932514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eversense (Senseonics) Continuous Glucose Monitoring System
Description: * Evaluate accuracy of Eversense CGM System to SMBG Meter.~* Compare performance between abdomen and arm insertion sites.~* Determine the usability of the Eversense System in a home-use setting for 180 days.
Study: NCT02095808

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Biomarkers
Description: Want to see if using 13C-glucose helps in detecting cancer and deciding on a treatment plan.
Study: NCT02255825

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole Genome Sequencing
Description: Whole genome sequencing in a CLIA lab and return of results.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniocentesis
Description: Note: this is being performed on all subjects as a clinical (not research) procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniocentesis
Description: Note: this is being performed on all subjects as a clinical (not research) procedure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial assessment
Description: Use of EPDS and STAI for assessment of maternal and paternal mood

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial assessment
Description: Use of EPDS and STAI for assessment of maternal and paternal mood
Study: NCT03823014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elator
Description: Measurement for device, use of device
Study: NCT04158700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200882
Description: LY3200882 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200882
Description: LY3200882 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200882
Description: LY3200882 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered IV
Study: NCT03370809

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brain PET/CT step
Description: a cerebral PET/CT will be registered on the 45th minute after 18F-FDG injection and just before the whole body recording. This recording does'nt need a new injection but needs a low dose scanner
Study: NCT02038907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A Vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A Vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A Vaccine IM injection
Study: NCT01323985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698
Description: IV (in the vein) single dose over 24 hours, in two sessions
Study: NCT01408277

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Santyl
Description: 2 mm Santyl applied once daily

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard Care
Study: NCT03943576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GXCPC1
Description: The dose regimen is one single intra-articular injection of GXCPC1 containing 6.7×10\^6 or 4×10\^7 ADSCs in 3 mL saline. (allogeneic injection)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA
Description: Hya Joint Plus synovial fluid supplement 3mL
Study: NCT03202433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of virtual reality lenses, with relaxing audio-visual contents
Description: Use of virtual reality lenses (and audio) as a distraction for the blood donor patients.
Study: NCT04458246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training group
Description: Online aerobic home-based exercise training, 3 times per week, during 3 months. The exercise program is composed by 3 levels (starter, intermediate and advanced) which be completed in the first, second and third month of intervention, respectively.
Study: NCT04619290

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control patients
Description: Control patients will be received the conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
Study: NCT02140645

Intervention type: DRUG
Intervention: linagliptin
Description: non-randomized
Study: NCT03562884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI800
Description: Two bottles of BLI800 are needed for appropriate cleansing of the bowel. Prior to administration, the content of each bottle must be diluted in water, using the cup provided, to a total volume of approximately 0.5 L, and must be followed by the ingestion of 1 additional litre of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fortrans®
Description: Fortrans® (Powder for Oral Solution) will be given according to Chinese approved Summary of Product Characteristics (SmPC). Fortrans® is provided as a powder for Polyethylene Glycol (PEG) based solution available in sachets containing a white powder readily miscible with water. The dosing for Fortrans® administration will be adapted to subjects' body weight as following: 1 L of solution for 15 to 20 kg, an average of 3 to 4 L (maximum 4 L).
Study: NCT03643900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pancreatic duct stenting
Description: Place the pancreatic duct stent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rectal indomethacin
Description: rectal indomethacin 100mg at preoperative 30min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rectal indomethacin
Description: rectal indomethacin 100mg at preoperative 30min
Study: NCT02480205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroBox to deliver the NeuroPAP
Description: The patients will be studied during the following conditions:~* On conventional NIPPV device with the clinically prescribed settings (30 min)~* With NeuroPAP and no change of Pmin (=peep) (60 min)~* With NeuroPAP and adjusted Pmin (decreased by 2 cmH2O) (60 min)~* During CPAP delivered with NeuroPAP device (15 min)~* Again with original NIPPV device and settings for 30 minutes
Study: NCT00531596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMSAM (Selegiline Transdermal System) 6mg/24Hr
Description: EMSAM 6mg/24HR
Study: NCT04241146

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enteric Tube
Description: A post pyloric feeding tube used in patients requiring enteral nutrition

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CORTRAK enteral access system
Description: Electromagnetic guidance system for enteric feeding tube placement
Study: NCT02181985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full dose TNK-tPA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Full dose TNK-tPA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half dose TNK-tPA
Study: NCT04384471

Intervention type: OTHER
Intervention: Online survey
Description: Participants are invited to answer an online questionnaire including both close-ended and open-ended questions about their experience during this sanitary crisis
Study: NCT02181985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Study: NCT03104985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASMIK
Description: the physiotherapeutic device LASMIK (Registration Certificate in Russia № RZN 2015/2687 dated 25.05.2015).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: * An elastic compression of lower extremities,~* Pharmacotherapy,~* Topical treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: * An elastic compression of lower extremities,~* Pharmacotherapy,~* Topical treatment
Study: NCT02876679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: GVHD prophylaxis: All patients will receive post-transplant 50mg/Kg/day cyclophosphamide (day +3 and +4) AND cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil in case of an HLA-matched unrelated donor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin
Description: GVHD prophylaxis: 2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1) All patients will receive cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil (MMF) in case of an HLA-matched unrelated donor.
Study: NCT02038907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A Vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A Vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A Vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A Vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A Vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A Vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A Vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A Vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection
Study: NCT02876679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conditioning regimen
Description: 30 mg/m2/day fludarabine for 5 days (day-6 to day-2) 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning regimen
Description: 30 mg/m2/day fludarabine for 5 days (day-6 to day-2) 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
Study: NCT00842361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: The insulin NN5401 (insulin degludec/insulin aspart) injected subcutaneously immediately before breakfast and dinner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: The insulin (biphasic insulin aspart 30) injected subcutaneously immediately before breakfast and dinner.
Study: NCT02481063

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 3 Consecutive Days Running at 80% Maximus Heart Rate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 3 Consecutive Days Running at 80% Maximus Heart Rate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric Overload
Description: Training with Eccentric Overload (Squat in Yoyo Technology) during 6 Weeks 3 Consecutive Days Running at 80% Maximus Heart Rate
Study: NCT02219997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clear clip-on glasses
Description: Clip-on glasses with no blue light filtering properties used as a placebo

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear clip-on glasses
Description: Clip-on glasses with no blue light filtering properties used as a placebo

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue light filter clip-on glasses
Description: Clip-on glasses with blue light filtering properties similar to ACRYSOF® IOLs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF® IQ IOL
Description: AcrySof IQ Aspheric Natural IOL Model SN60WF with UV and blue light filtering properties, previously implanted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear IOL
Description: Clear IOL, previously implanted
Study: NCT01432093

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive glycemic management
Description: Intravenous insulin infusion, strict dietary intervention, carbohydrate matched subcutaneous insulin therapy. This is a multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional management
Description: Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
Study: NCT04907318

Intervention type: DEVICE
Intervention: Cataract surgery

Intervention type: DEVICE
Intervention: Cataract surgery
Study: NCT04270487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IBS Diet
Description: Patients will be randomized to a diet or a mediation treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Otilonium Bromide
Description: Patients will be randomized to a diet or a mediation treatment
Study: NCT05366257

Intervention type: OTHER
Intervention: CAR-T
Description: infusion of CAR-T therapy among patients with r/r DLBCL

Intervention type: OTHER
Intervention: CAR-T
Description: infusion of CAR-T therapy among patients with r/r DLBCL

Intervention type: OTHER
Intervention: Allo-HSCT cohort
Description: Patients received allogeneic hematopoietic stem cell transplant
Study: NCT03895970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab
Description: Lenvatinib 12mg, once a day, oral at least 38 days of each 6 weeks cycle. Pembrolizumab 200mg, every 3 weeks, intravenous infused of each 6 weeks cycle. Number of cycle: until progression or unacceptable toxicity develops.
Study: NCT02988401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: All patients will receive either insulin or placebo using the Vianase III N2B device during the first 24 weeks of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: All patients will receive either insulin or placebo using the Vianase III N2B device during the first 24 weeks of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sterile diluent)
Description: All patients will receive either insulin or placebo using Vianase III N2B device during the first 24 weeks of the study.
Study: NCT03404518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norco
Description: Hydrocodone/Acetaminophen as first line therapy every 6 hours as needed for pain control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen as first line therapy every 6 hours as needed for pain control
Study: NCT02406053

Intervention type: GENETIC
Intervention: oxidative and antioxidant biomarkers
Description: the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.

Intervention type: GENETIC
Intervention: oxidative and antioxidant biomarkers
Description: the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.

Intervention type: GENETIC
Intervention: oxidative and antioxidant biomarkers
Description: the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.

Intervention type: GENETIC
Intervention: oxidative and antioxidant biomarkers
Description: the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.
Study: NCT04285853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 5 mg oxycodone pills every 4-6 hrs if pain level 7 or higher on Numeric rating scale 1-10

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo tablets (both trial and rescue) will be matched to size, shape, color, and texture of oxycodone tablets.
Study: NCT02376491

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation